Eli Lilly announced agreements to acquire three private vaccine developers—Vaccine Co., Curevo, and LimmaTech Biologics—expanding its infectious-disease pipeline through a series of transactions that could total nearly $4 billion. The deals deepen Lilly’s effort to pivot from treating downstream complications to preventing disease at its source. Curevo’s lead candidate is an experimental shingles vaccine using a next-generation synthetic adjuvant; Lilly said it produced a similar immune response to a standard shingles shot in Phase 2 while showing fewer side effects. LimmaTech Biologics is focused on bacterial vaccines in a field shaped by antimicrobial resistance concerns. Lilly framed the acquisitions as aligned with its infectious-disease leadership, including the hiring of FDA’s former vaccine chief Peter Marks. The move follows Lilly’s other major activity across modalities and geographies, with company cash flow supported by obesity and diabetes sales. For vaccine developers, the transaction bundle signals continued valuation appetite from large-cap pharma for platforms and clinical-stage assets that can scale into broader prevention programs.